J Neurosci Res (2018) 96(6):92750
Food and Drug Administration (FDA) for once-weekly CagriSema (cagrilintide 2.4 mg and semaglutide 2.4 mg) injection, to be used with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight in the presence of at least one weight-related comorbid condition
14,15 The second step is the use of pharmacologic medications, including metformin, oral sulphonylureas, oral sodium-glucose cotransporter 2 (SGLT2) inhibitors, oral dipeptidyl peptidase 4 (DPP-4) inhibitors, oral -Glucosidase, injectable glucagon-like peptide 1 (GLP1) receptor agonists, or injectable insulin
10.3390/ijms21051711 188 HopfnerF.KnstnerA.MllerS
Immunol Res, 2009
doi: 10.3201/eid0911.030143 34 CarruthersVBSuzukiY